Back to Search Start Over

Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3.

Authors :
Tasso B
Mattioli LB
Tonelli M
Boido V
Chiarini A
Sparatore F
Budriesi R
Source :
Molecules (Basel, Switzerland) [Molecules] 2023 Oct 03; Vol. 28 (19). Date of Electronic Publication: 2023 Oct 03.
Publication Year :
2023

Abstract

Fourteen quinolizidine derivatives, structurally related to the alkaloids lupinine and cytisine and previously studied for other pharmacological purposes, were presently tested for antiarrhythmic, and other cardiovascular effects on isolated guinea pig heart tissues in comparison to well-established reference drugs. According to their structures, the tested compounds are assembled into three subsets: (a) N-(quinolizidinyl-alkyl)-benzamides; (b) 2-(benzotriazol-2-yl)methyl-1-(quinolizidinyl)alkyl-benzimidazoles; (c) N-substituted cytisines. All compounds but two displayed antiarrhythmic activity that was potent for compounds 4 , 1 , 6 , and 5 (in ascending order). The last compound (N-(3,4,5-trimethoxybenzoyl)aminohomolupinane) was outstanding, exhibiting a nanomolar potency (EC <subscript>50</subscript> = 0.017 µM) for the increase in the threshold of ac-arrhythmia. The tested compounds shared strong negative inotropic activity; however, this does not compromise the value of their antiarrhythmic action. On the other hand, only moderate or modest negative chronotropic and vasorelaxant activities were commonly observed. Compound 5 , which has high antiarrhythmic potency, a favorable cardiovascular profile, and is devoid of antihypertensive activity in spontaneously hypertensive rats, represents a lead worthy of further investigation.

Details

Language :
English
ISSN :
1420-3049
Volume :
28
Issue :
19
Database :
MEDLINE
Journal :
Molecules (Basel, Switzerland)
Publication Type :
Academic Journal
Accession number :
37836759
Full Text :
https://doi.org/10.3390/molecules28196916